Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H14O3 |
| Molecular Weight | 194.2271 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)COC(=O)C1=CC=C(O)C=C1
InChI
InChIKey=XPJVKCRENWUEJH-UHFFFAOYSA-N
InChI=1S/C11H14O3/c1-8(2)7-14-11(13)9-3-5-10(12)6-4-9/h3-6,8,12H,7H2,1-2H3
| Molecular Formula | C11H14O3 |
| Molecular Weight | 194.2271 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | surmontil Approved UseSurmontil is indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. Launch Date1979 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive [IC50 5.0406 uM] | ||||
| inconclusive [IC50 70.922 uM] | ||||
| no [EC50 4.8508 uM] | ||||
| no | ||||
| yes [IC50 10.1 uM] | ||||
| yes [IC50 2.8235 uM] | ||||
| yes [IC50 25.1641 uM] | ||||
| yes [IC50 3.168 uM] | ||||
| yes [IC50 36.4 uM] | ||||
| yes [IC50 36.4 uM] | ||||
| yes [IC50 7.72 uM] | ||||
| yes [IC50 80.6 uM] | ||||
| yes [IC50 94.6 uM] | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes [Km 32.6 uM] | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative study on transcriptional activity of 17 parabens mediated by estrogen receptor α and β and androgen receptor. | 2013-07 |
|
| Additional effects of bisphenol A and paraben on the induction of calbindin-D(9K) and progesterone receptor via an estrogen receptor pathway in rat pituitary GH3 cells. | 2012-10 |
|
| Potential estrogenic effect(s) of parabens at the prepubertal stage of a postnatal female rat model. | 2010-06 |
|
| Urinary concentrations of four parabens in the U.S. population: NHANES 2005-2006. | 2010-05 |
|
| In vitro study of Organization for Economic Co-operation and Development (OECD) endocrine disruptor screening and testing methods- establishment of a recombinant rat androgen receptor (rrAR) binding assay. | 2010-04 |
|
| Mixture effects of endocrine disrupting compounds in vitro. | 2010-04 |
|
| Validation of an in vitro screening test for predicting the tumor promoting potential of chemicals based on gene expression. | 2010-04 |
|
| Maternal exposure to isobutyl-paraben impairs social recognition in adult female rats. | 2010 |
|
| [Determination of six p-hydroxybenzoates in fruits and jams using solid-phase extraction-high performance liquid chromatography]. | 2009-11 |
|
| An evaluation of estrogenic activity of parabens using uterine calbindin-d9k gene in an immature rat model. | 2009-11 |
|
| Maternal isobutyl-paraben exposure alters anxiety and passive avoidance test performance in adult male rats. | 2009-10 |
|
| Maternal isobutyl-paraben exposure decreases the plasma corticosterone level in dams and sensitivity to estrogen in female offspring rats. | 2009-08 |
|
| Removal of estrogenic activity of iso-butylparaben and n-butylparaben by laccase in the presence of 1-hydroxybenzotriazole. | 2009-07 |
|
| Parabens in male infertility-is there a mitochondrial connection? | 2009-01 |
|
| Evaluation of estrogenic activity of parabens and their chlorinated derivatives by using the yeast two-hybrid assay and the enzyme-linked immunosorbent assay. | 2009-01 |
|
| Underarm antiperspirants/deodorants and breast cancer. | 2009 |
|
| Simultaneous determination of 21 preservatives in cosmetics by ultra performance liquid chromatography. | 2008-10 |
|
| Construction of simplified models to simulate estrogenic disruptions by esters of 4-hydroxy benzoic acid (parabens). | 2008-09 |
|
| Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products. | 2008 |
|
| [Simultaneous determination of 7 kinds of preservatives and saccharin in foods with HPLC, and identification with LC/MS/MS]. | 2007-12 |
|
| [Simultaneous determination of nine kinds of preservatives in foods by HPLC]. | 2007-06 |
|
| Preliminary ecological risk assessment of butylparaben and benzylparaben -2. Fate and partitioning in aquatic environments. | 2007 |
|
| Preliminary ecological risk assessment of butylparaben and benzylparaben -1. Removal efficiency in wastewater treatment, acute/chronic toxicity for aquatic organisms, and effects on medaka gene expression. | 2007 |
|
| Parabens as urinary biomarkers of exposure in humans. | 2006-12 |
|
| Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006-11 |
|
| A review of the endocrine activity of parabens and implications for potential risks to human health. | 2005-06 |
|
| Uterotrophic effects of benzophenone derivatives and a p-hydroxybenzoate used in ultraviolet screens. | 2005-05 |
|
| Oestrogenic activity of benzylparaben. | 2003-01-09 |
|
| Oestrogenic activity of isobutylparaben in vitro and in vivo. | 2002-09-05 |
|
| ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERalpha and PR. | 2001-12 |
|
| [Competitive binding of some alkyl p-hydroxybenzoates to human estrogen receptor alpha and beta]. | 2000-12 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:37 GMT 2025
by
admin
on
Mon Mar 31 17:50:37 GMT 2025
|
| Record UNII |
0QQJ25X58G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C92608
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
0QQJ25X58G
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
20240
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
0QQJ25X58G
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
DTXSID4020749
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
4247-02-3
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
C92610
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
100000128931
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
224-208-8
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
1364296
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB36797
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY | |||
|
C471067
Created by
admin on Mon Mar 31 17:50:37 GMT 2025 , Edited by admin on Mon Mar 31 17:50:37 GMT 2025
|
PRIMARY |